- Other backers included General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners LP, and Samsara BioCapital
- In addition to the funding, Shelley Chu, head of Lightspeed Venture Partners’ healthcare team and Evan Rachlin, co-founder and managing partner of Ascenta Capital will join the Alpha-9’s board of directors
- The capital infusion will be used to fund human studies for the clinical stage assets and advancement of discovery stage assets to clinic-ready development candidates
Alpha-9 Oncology Inc, a Boston and Canadian clinical-stage radiopharmaceutical company, has raised $175 million in Series C funding.
Lightspeed Venture Partners and Ascenta Capital led the round.
Other backers included General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners LP, and Samsara BioCapital.
In addition to the funding, Shelley Chu, head of Lightspeed Venture Partners’ healthcare team and Evan Rachlin, co-founder and managing partner of Ascenta Capital will join the Alpha-9’s board of directors.
The capital infusion will be used to fund human studies for the clinical stage assets and advancement of discovery stage assets to clinic-ready development candidates. Also, the Series C will fund expanded R&D capabilities and continued investment in CMC and supply chain.
“Alpha-9 is developing a differentiated portfolio that includes multiple radiopharmaceuticals with first-in-class and best-in-class potential,” said Shelley Chu, head of Lightspeed Venture Partners’ healthcare team in a statement. “We are impressed with the team’s progress to date and are proud to support the advancement of these programs.”
Lightspeed Venture Partners invests in the enterprise, healthcare, consumer and fintech sectors. Lightspeed and its global team currently manage $25 billion in assets under management.
Ascenta Capital is a biotech venture firm co-founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim.
- Other backers included General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners LP, and Samsara BioCapital
- In addition to the funding, Shelley Chu, head of Lightspeed Venture Partners’ healthcare team and Evan Rachlin, co-founder and managing partner of Ascenta Capital will join the Alpha-9’s board of directors
- The capital infusion will be used to fund human studies for the clinical stage assets and advancement of discovery stage assets to clinic-ready development candidates
Alpha-9 Oncology Inc, a Boston and Canadian clinical-stage radiopharmaceutical company, has raised $175 million in Series C funding.
Lightspeed Venture Partners and Ascenta Capital led the round.
Other backers included General Catalyst, a16z Bio + Health, RA Capital Management, Janus Henderson Investors, Delos Capital, Digitalis Ventures, Frazier Life Sciences, Longitude Capital, Nextech Invest, BVF Partners LP, and Samsara BioCapital.
In addition to the funding, Shelley Chu, head of Lightspeed Venture Partners’ healthcare team and Evan Rachlin, co-founder and managing partner of Ascenta Capital will join the Alpha-9’s board of directors.
The capital infusion will be used to fund human studies for the clinical stage assets and advancement of discovery stage assets to clinic-ready development candidates. Also, the Series C will fund expanded R&D capabilities and continued investment in CMC and supply chain.
“Alpha-9 is developing a differentiated portfolio that includes multiple radiopharmaceuticals with first-in-class and best-in-class potential,” said Shelley Chu, head of Lightspeed Venture Partners’ healthcare team in a statement. “We are impressed with the team’s progress to date and are proud to support the advancement of these programs.”
Lightspeed Venture Partners invests in the enterprise, healthcare, consumer and fintech sectors. Lightspeed and its global team currently manage $25 billion in assets under management.
Ascenta Capital is a biotech venture firm co-founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim.
